Syntimmune has got off a beefy $50 million series B round.

German Merck and R&D charity CRUK are coming together to launch a biotech focused on immuno-oncology.

EvaluatePharma has totted up the figures for R&D spend and costs for biopharmas, and the figures are huge.

Filings for brolucizumab are expected next year, with analysts at Jefferies predicting $2 billion in peak sales for the drug.

Gamida Cell has upped its financing by $40 million in its latest funding round to prep for final work on a late-stage stem cell blood cancer therapy.

Sean Parker’s immuno-oncology institute has allied with Tessa Therapeutics to turn T-cell therapies against solid tumors.

An Ernst & Young report shows a mixed bag across the whole sector.

Bavarian Nordic has again delayed the release of data from a phase 3 trial of Prostvac.

J&J has unveiled another clutch of deals and collaborations with industry and academia.

Probably hoping to help turn things around after clinical setbacks, microRNA biotech Regulus tapped the help of CRO Aptuit.

R&D